Results 171 to 180 of about 73,209 (288)

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations

open access: yesAmerican Journal of Hematology, Volume 101, Issue 1, Page 41-55, January 2026.
ABSTRACT Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma. The success of asparaginase‐containing regimens has led to trials of pediatric/pediatric‐inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations with acute ...
Ibrahim Aldoss   +7 more
wiley   +1 more source

The Effects of Bone‐Remodeling Therapy on Survival, Pain, and Skeletal Related Events in the Setting of Renal Cell Carcinoma With Bone Metastases: A Multicenter Investigation From a Large Global Health Research Network (TriNetX)

open access: yesCancer Medicine, Volume 15, Issue 1, January 2026.
In this retrospective population study containing 139,859 patients, subjects receiving RANK‐ligand inhibitors had improved survival and decreased rates of skeletal‐related events relative to the overall cohort of patients with metastatic bone lesions.
Brian H. Im   +9 more
wiley   +1 more source

Successful Treatment of Recurrent Painful Muscle Spasms After Total Hip Arthroplasty With Oxcarbazepine: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Painful muscle spasms are characterized by sudden onset of involuntary muscle contractions accompanying severe pain. The occurrence of painful muscle spasms after total hip arthroplasty (THA) is extremely rare in clinical practice. We report a case in which a patient developed painful muscle spasms after THA, and symptoms were controlled by ...
Youhan Yang   +3 more
wiley   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 120-130, January 2026.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb‐oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of ...
Eleanor A. Lisbon   +15 more
wiley   +1 more source

Bilibili and TikTok as sources of medical information on osteonecrosis of the femoral head: A cross-platform content analysis. [PDF]

open access: yesDigit Health
Wei B   +14 more
europepmc   +1 more source

Natural‐History Mapping of Lysosomal Storage Disorders (LSDs): Gaucher Disease as a Model for Precision Care

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 1, January 2026.
ABSTRACT Natural‐history datasets have become pivotal for drug development and for shaping clinical‐practice guidelines in rare diseases, yet many lysosomal storage disorders would benefit from deep phenotyping and modern analytic methods. Our objective was to integrate the past decade of genomic, cellular, treatment‐outcome, and regulatory advances ...
Noor Ul Ain   +2 more
wiley   +1 more source

In Vitro Evaluation of Hemiarthroplasty Bearing Materials: A Scoping Review (Part I)

open access: yesJournal of Orthopaedic Research, Volume 44, Issue 1, January 2026.
ABSTRACT Hemiarthroplasty is used to treat joint damage confined to one side, aiming to preserve the remaining healthy cartilage and bone while addressing conditions like femur fractures and osteonecrosis; however, challenges persist due to cartilage wear and inconsistent clinical outcomes.
Victoria P. Marino   +6 more
wiley   +1 more source

Vertebral body osteonecrosis: Evolving imaging features over time. [PDF]

open access: yesRadiol Case Rep
Masino F   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy